[144] GLAUKOS Corp SEC Filing

Rhea-AI Filing Summary

Glaukos Corporation (GKOS)19,340 common shares under Rule 144. The shares will be sold through Fidelity Brokerage Services LLC on or about 11/18/2025 on the NYSE, with an indicated aggregate market value of $1,740,600. The filing notes that 57,434,740 common shares were outstanding. Most of the shares being sold were acquired between March 2023 and April 2024 through restricted stock vesting as compensation, along with a smaller amount purchased through the company’s employee stock purchase plan. The signer represents that they are not aware of undisclosed material adverse information about Glaukos.

11/18/2025 - 12:41 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	19340	1740600.00	57434740	11/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/14/2023	Restricted Stock Vesting	Issuer			909	03/14/2023	Compensation
Common	03/24/2023	Restricted Stock Vesting	Issuer			5394	03/24/2023	Compensation
Common	04/01/2023	Restricted Stock Vesting	Issuer			2307	04/01/2023	Compensation
Common	06/30/2023	ESPP Purchase	Issuer			569	06/30/2023	Cash
Common	08/02/2023	Restricted Stock Vesting	Issuer			892	08/02/2023	Compensation
Common	01/01/2024	Restricted Stock Vesting	Issuer			191	01/01/2024	Compensation
Common	03/13/2024	Restricted Stock Vesting	Issuer			958	03/13/2024	Compensation
Common	03/22/2024	Restricted Stock Vesting	Issuer			2315	03/22/2024	Compensation
Common	03/24/2024	Restricted Stock Vesting	Issuer			4066	03/24/2024	Compensation
Common	04/01/2024	Restricted Stock Vesting	Issuer			1739	04/01/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Glaukos (GKOS) Form 144 filing report?

The Form 144 reports that a Glaukos affiliate intends to sell 19,340 shares of common stock under Rule 144 on the NYSE through Fidelity Brokerage Services LLC.

How many Glaukos (GKOS) shares are planned to be sold and what is their value?

The holder plans to sell 19,340 common shares of Glaukos with an indicated aggregate market value of $1,740,600.

How many Glaukos (GKOS) shares were outstanding according to this notice?

The notice states that 57,434,740 common shares of Glaukos were outstanding when the Form 144 was prepared.

When and where are the Glaukos (GKOS) shares expected to be sold?

The filing lists an approximate sale date of 11/18/2025 and names the NYSE as the securities exchange for the planned sale.

How did the seller acquire the Glaukos (GKOS) shares being sold under Form 144?

The shares were mainly acquired from the issuer through restricted stock vesting as compensation between March 2023 and April 2024, plus some purchased via an employee stock purchase plan.

Does the Glaukos (GKOS) Form 144 include any representation about undisclosed information?

Yes. By signing, the person for whose account the securities are to be sold represents that they do not know of any undisclosed material adverse information about Glaukos’s current or prospective operations.